Experimental compound helps burn fat without muscle loss
Researchers at UC Berkeley have identified a molecular compound called TOFA that increases metabolic activity to burn fat without causing muscle loss. This approach offers a potential alternative to current GLP-1 weight-loss drugs, which often lead to muscle depletion.
Why it matters
It provides a new therapeutic pathway for treating obesity and diabetes that preserves lean muscle mass, addressing a major side effect of current blockbuster medications.
GLP-1 medications have transformed the treatment of obesity, diabetes, and fatty liver disease over the past several years. Drugs sold as Ozempic, Wegovy, Mounjaro, and Zepbound can produce substantial weight loss while helping patients control blood sugar.
But these medications can also cause problems. Some patients experience nausea and other gastrointestinal side effects. Because GLP-1 drugs reduce appetite and food intake, they may also contribute to nutritional deficiencies and loss of muscle, potentially increasing the risk of frailty and other long-term health issues.
Researchers at UC Berkeley are now investigating a very different strategy for treating obesity and diabetes. Instead of reducing the amount of energy a person consumes, their approach is designed to increase the amount of energy the body uses by raising metabolic activity.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in